Gilead Sciences reports $6.96 billion revenue for quarter ended March 31, 2026, up 4.4%
Gilead Sciences reported revenue of $6.96 billion for the quarter ended March 31, 2026, an increase of 4.4% from the same quarter a year earlier ($6.67 billion).
For the same period it posted net income of $2.02 billion, up 53.7%, or $1.61 per diluted share (1.04 a year earlier).
That is a net margin of 29%.
On Sanad's AAOIFI Standard 21 screen, Gilead Sciences is currently compliant: interest-bearing debt is 12.4% of market capitalisation (limit 30%), and impure income is 1.2% of revenue (limit 5%).
Is Gilead Sciences halal?
See the full AAOIFI screening of Gilead Sciences
See the full AAOIFI screening of Gilead Sciences
Source: 10-Q filed with the U.S. Securities and Exchange Commission on May 7, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.